Study 18 of 40 for search of: "Mumps"
Previous Study Return to Search Results Next Study

  Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Immunogenicity/Safety of Measles-Mumps-Rubella-Varicella Vaccine (MeMuRu-OKA): Using Two Different Administration Routes
This study has been completed.
Sponsored by: GlaxoSmithKline
Information provided by: GlaxoSmithKline
ClinicalTrials.gov Identifier: NCT00351923
  Purpose

This study will compare the immunogenicity and safety of the MeMuRu-OKA vaccine administered subcutaneously or using an alternative administration route.


Condition Intervention Phase
Measles
Mumps
Rubella
Varicella
Biological: MeMuRu-OKA (study vaccine)
Phase III

MedlinePlus related topics: Chickenpox Measles Mumps Rubella Shingles
Drug Information available for: Chickenpox Vaccine
U.S. FDA Resources
Study Type: Interventional
Study Design: Prevention, Randomized, Open Label, Parallel Assignment, Safety/Efficacy Study
Official Title: Open, Multicenter, Randomised, Controlled Phase IIIb Study Evaluating the Immunogenicity and Safety of Subcutaneous Versus Alternative Administration Route of Combined MeMuRu-OKA Vaccine to Healthy Children Aged 11 to 21 Months.

Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:
  • Seroconversion rates after vaccination

Secondary Outcome Measures:
  • Antibody titres; safety: solicited local/ general, unsolicited AEs (42 days), SAEs (whole study)

Estimated Enrollment: 330
Study Start Date: March 2006
Study Completion Date: December 2006
  Eligibility

Ages Eligible for Study:   11 Months to 22 Months
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Children must be healthy and have a birth weight > 2000 g to participate

Exclusion Criteria:

  • confirmed or suspected tuberculosis, immunosuppressive (including HIV) conditions, neurological disorders, history of allergic disease or reaction, major congenital defects, chronical administration of salicylates, and fever (axillary temperature ³ 37.5°C at the time of vaccination) are excluding factors.
  • Children from pregnant mothers who have a negative history of chickenpox are also excluded from the study.
  • Children must have received one dose (but not more) of MMR and of varicella at least 6 weeks before entering the study. They must not receive or have received other non-registered drug or vaccine within 30 days prior to study start, or immunosuppressants for more than 14 days.
  • Immunoglobulins or any blood products are prohibited during the 6 months before and during the study, as well as vaccine other than that foreseen by the protocol within 30 days before vaccination.
  • Children must not have had measles, mumps, rubella or varicella/zoster, or have been exposed to those diseases within 30 days prior to study start.
  • New-born infants (< 5 weeks of age), pregnant women without previous exposure to chickenpox, and immunodeficient persons cannot live in the same household as the vaccinated child
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00351923

Locations
Germany, Baden-Wuerttemberg
GSK Investigational Site
Mannheim, Baden-Wuerttemberg, Germany, 68167
GSK Investigational Site
Stuttgart, Baden-Wuerttemberg, Germany, 70469
GSK Investigational Site
Tauberbischofsheim, Baden-Wuerttemberg, Germany, 97941
GSK Investigational Site
Ettenheim, Baden-Wuerttemberg, Germany, 77955
GSK Investigational Site
Bretten, Baden-Wuerttemberg, Germany, 75015
GSK Investigational Site
Oberkirch, Baden-Wuerttemberg, Germany, 77704
GSK Investigational Site
Kehl, Baden-Wuerttemberg, Germany, 77694
GSK Investigational Site
Schwaebisch-Hall, Baden-Wuerttemberg, Germany, 74523
GSK Investigational Site
Karlsruhe, Baden-Wuerttemberg, Germany, 76189
GSK Investigational Site
Boennigheim, Baden-Wuerttemberg, Germany, 74357
GSK Investigational Site
Offenburg, Baden-Wuerttemberg, Germany, 77654
Germany, Hessen
GSK Investigational Site
Giessen, Hessen, Germany, 35390
GSK Investigational Site
Eschwege, Hessen, Germany, 37269
Germany, Rheinland-Pfalz
GSK Investigational Site
Bad Kreuznach, Rheinland-Pfalz, Germany, 55543
GSK Investigational Site
Trier, Rheinland-Pfalz, Germany, 54290
GSK Investigational Site
Trier, Rheinland-Pfalz, Germany, 54294
GSK Investigational Site
Mainz, Rheinland-Pfalz, Germany, 55131
GSK Investigational Site
Worms, Rheinland-Pfalz, Germany, 67547
GSK Investigational Site
Mainz, Rheinland-Pfalz, Germany, 55127
GSK Investigational Site
Frankenthal, Rheinland-Pfalz, Germany, 67227
Sponsors and Collaborators
GlaxoSmithKline
Investigators
Study Director: GSK Clinical Trials GlaxoSmithKline
  More Information

Responsible Party: GSK ( Study Director )
Study ID Numbers: 106670
Study First Received: July 12, 2006
Last Updated: October 9, 2008
ClinicalTrials.gov Identifier: NCT00351923  
Health Authority: Germany: Paul-Ehrlich-Institut

Study placed in the following topic categories:
Herpes Zoster
Mouth Diseases
Paramyxoviridae Infections
Measles
Chickenpox
Healthy
Rubella
Togaviridae Infections
Herpesviridae Infections
Virus Diseases
DNA Virus Infections
Chicken pox
Stomatognathic Diseases
Salivary Gland Diseases
Mumps

Additional relevant MeSH terms:
Rubivirus Infections
Parotid Diseases
RNA Virus Infections
Morbillivirus Infections
Rubulavirus Infections
Parotitis
Mononegavirales Infections

ClinicalTrials.gov processed this record on January 16, 2009